Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription


1 Am J Clin Pathol
1 Am J Pathol
4 Ann Oncol
9 Ann Surg Oncol
5 Anticancer Res
8 BMC Cancer
1 Breast Cancer
2 Breast Cancer (Auckl)
4 Breast Cancer (Dove Med Press)
2 Breast Cancer Res
20 Breast Cancer Res Treat
2 Cancer
2 Cancer Chemother Pharmacol
2 Cancer Epidemiol Biomarkers Prev
3 Cancer Lett
3 Cancer Res
3 Clin Breast Cancer
7 Clin Cancer Res
1 Curr Treat Options Oncol
6 Eur J Cancer
1 Eur Radiol
1 Gene
4 Int J Cancer
2 Int J Radiat Oncol Biol Phys
4 J Clin Oncol
5 J Natl Cancer Inst
1 J Nucl Med
1 J Pathol
2 Lancet Oncol
1 N Engl J Med
1 Nature
8 NPJ Breast Cancer
3 Oncogene
1 Oncol Rep
1 Oncology
10 PLoS One
2 Radiology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Pathol

  1. MUGABE M, Ho KE, Ruhangaza D, Milner D, et al
    Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing Country.
    Am J Clin Pathol. 2021 May 29. pii: 6288023. doi: 10.1093.
    PubMed         Abstract available

    Am J Pathol

    Involvement of the Tumor Microenvironment in the Pathogenesis of Breast Cancer.
    Am J Pathol. 2021 Jun 4. pii: S0002-9440(21)00246.

    Ann Oncol

  3. SLAMON DJ, Neven P, Chia S, Jerusalem G, et al
    Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.
    Ann Oncol. 2021 May 15. pii: S0923-7534(21)01553.
    PubMed         Abstract available

  4. PICCART MJ, Kalinsky K, Gray R, Barlow WE, et al
    Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.
    Ann Oncol. 2021 May 31. pii: S0923-7534(21)02029.

    Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study.
    Ann Oncol. 2021 May 28. pii: S0923-7534(21)02027.

  6. BARDIA A, Tolaney SM, Punie K, Loirat D, et al
    Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
    Ann Oncol. 2021 Jun 8. pii: S0923-7534(21)02047.
    PubMed         Abstract available

    Ann Surg Oncol

  7. PRATT D, Burneikis T, Tu C, Grobmyer S, et al
    Time to Completion of Breast Cancer Treatment and Survival.
    Ann Surg Oncol. 2021 Jun 8. pii: 10.1245/s10434-021-10116.
    PubMed         Abstract available

  8. JIWA N, Gandhewar R, Chauhan H, Ashrafian H, et al
    Diagnostic Accuracy of Nipple Aspirate Fluid Cytology in Asymptomatic Patients: A Meta-analysis and Systematic Review of the Literature.
    Ann Surg Oncol. 2021;28:3751-3760.
    PubMed         Abstract available

    ASO Author Reflections: Metastasis of Inflammatory Breast Cancer to the Contralateral Axilla: A Finding Meriting Further Study.
    Ann Surg Oncol. 2021 Jun 2. pii: 10.1245/s10434-021-10208.

  10. CHEN G, Jia M, Zeng Q, Zhang H, et al
    ASO Visual Abstract: Development and Validation of Web-Based Nomograms for Predicting Cause-Specific Mortality in Surgically Resected Nonmetastatic Invasive Breast Cancer: A Population-Based Study.
    Ann Surg Oncol. 2021 Jun 2. pii: 10.1245/s10434-021-10154.

  11. POSTLEWAIT LM, Teshome M, Adesoye T, DeSnyder SM, et al
    ASO Visual Abstract: Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer.
    Ann Surg Oncol. 2021 May 29. pii: 10.1245/s10434-021-10200.

  12. TASKINDOUST M, Thomas SM, Sammons SL, Fayanju OM, et al
    Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients.
    Ann Surg Oncol. 2021 May 28. pii: 10.1245/s10434-021-10227.
    PubMed         Abstract available

  13. CHEN G, Jia M, Zeng Q, Zhang H, et al
    Development and Validation of Web-Based Nomograms for Predicting Cause-Specific Mortality in Surgically Resected Nonmetastatic Invasive Breast Cancer: A Population-Based Study.
    Ann Surg Oncol. 2021 Jun 10. pii: 10.1245/s10434-021-10129.
    PubMed         Abstract available

  14. PRATT D, Grobmyer SR
    ASO Author Reflections: Time to Treatment: A New Quality Metric in Breast Cancer Care?
    Ann Surg Oncol. 2021 May 28. pii: 10.1245/s10434-021-10169.

  15. CLARKE CN, Cortina CS, Fayanju OM, Dossett LA, et al
    Breast Cancer Risk and Screening in Transgender Persons: A Call for Inclusive Care.
    Ann Surg Oncol. 2021 Jun 7. pii: 10.1245/s10434-021-10217.
    PubMed         Abstract available

    Anticancer Res

  16. WALL TP, Crowley PD, Buggy DJ
    The Effect of Lidocaine and Bosutinib on 4T1 Murine Breast Cancer Cell Behaviour In Vitro.
    Anticancer Res. 2021;41:2835-2840.
    PubMed         Abstract available

  17. KRAWCZYK N, Janowski K, Banys-Paluchowski M, Staebler A, et al
    The SOX2 Status of Disseminated Tumor Cells in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2021;41:2849-2858.
    PubMed         Abstract available

  18. KIM K, Chun M, Jin H, Jung W, et al
    Inter-institutional Variation in Intensity-modulated Radiotherapy for Breast Cancer in Korea (KROG 19-01).
    Anticancer Res. 2021;41:3145-3152.
    PubMed         Abstract available

  19. MIKI M, Takao S, Konishi M, Shigeoka Y, et al
    Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
    Anticancer Res. 2021;41:3121-3126.
    PubMed         Abstract available

  20. AKAGI H, Shimada A, Chin K, Domoto H, et al
    Successful Stabilization of Symptomatic Bone Marrow Metastasis Two Times in a Breast Cancer Patient.
    Anticancer Res. 2021;41:3139-3144.
    PubMed         Abstract available

    BMC Cancer

  21. HUANG S, Hu P, Lakowski TM
    Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
    BMC Cancer. 2021;21:648.
    PubMed         Abstract available

  22. WANG D, Wei G, Ma J, Cheng S, et al
    Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients.
    BMC Cancer. 2021;21:645.
    PubMed         Abstract available

  23. FOSTER M, Niedzwiedz CL
    Associations between multimorbidity and depression among breast cancer survivors within the UK Biobank cohort: a cross-sectional study.
    BMC Cancer. 2021;21:650.
    PubMed         Abstract available

  24. LIU Y, Teng L, Fu S, Wang G, et al
    Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    BMC Cancer. 2021;21:644.
    PubMed         Abstract available

  25. MCWILLIAMS L, Woof VG, Donnelly LS, Howell A, et al
    Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?
    BMC Cancer. 2021;21:637.
    PubMed         Abstract available

  26. WOO J, Oh SJ, Song JY, Chae BJ, et al
    Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study.
    BMC Cancer. 2021;21:647.
    PubMed         Abstract available

  27. BORRERO-GARCIA LD, Del Mar Maldonado M, Medina-Velazquez J, Troche-Torres AL, et al
    Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
    BMC Cancer. 2021;21:652.
    PubMed         Abstract available

  28. BREIDENBACH C, Wesselmann S, Sibert NT, Ortmann O, et al
    Use of social service counseling by cancer patients: an analysis of quality assurance data of 6339 breast cancer patients from 13 certified centers in Germany treated between 2015 and 2017.
    BMC Cancer. 2021;21:671.
    PubMed         Abstract available

    Breast Cancer

  29. LIN Y, Xu Y, Wang C, Song Y, et al
    Loco-regional therapy and the risk of breast cancer-related lymphedema: a systematic review and meta-analysis.
    Breast Cancer. 2021 Jun 9. pii: 10.1007/s12282-021-01263.
    PubMed         Abstract available

    Breast Cancer (Auckl)

  30. YUE W, Tran HT, Wang JP, Schiermeyer K, et al
    The Hypertension Related Gene G-Protein Coupled Receptor Kinase 4 Contributes to Breast Cancer Proliferation.
    Breast Cancer (Auckl). 2021;15:11782234211015753.
    PubMed         Abstract available

  31. DARRE T, Tchaou M, Djiwa T, Douaguibe B, et al
    Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings.
    Breast Cancer (Auckl). 2021;15:11782234211020242.
    PubMed         Abstract available

    Breast Cancer (Dove Med Press)

  32. MARTELLI V, Latocca MM, Ruelle T, Perachino M, et al
    Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women.
    Breast Cancer (Dove Med Press). 2021;13:341-351.
    PubMed         Abstract available

  33. SILVA ROCHA F, da Silva Maues JH, Brito Lins Pereira CM, Moreira-Nunes CA, et al
    Analysis of Increased EGFR and IGF-1R Signaling and Its Correlation with Socio-Epidemiological Features and Biological Profile in Breast Cancer Patients: A Study in Northern Brazil.
    Breast Cancer (Dove Med Press). 2021;13:325-339.
    PubMed         Abstract available

  34. ULRICH L, Okines AFC
    Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib.
    Breast Cancer (Dove Med Press). 2021;13:361-381.
    PubMed         Abstract available

  35. SAVIOLI F, Seth S, Morrow E, Doughty J, et al
    Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer.
    Breast Cancer (Dove Med Press). 2021;13:353-359.
    PubMed         Abstract available

    Breast Cancer Res

  36. HAN Y, Lv J, Yu C, Guo Y, et al
    Development and external validation of a breast cancer absolute risk prediction model in Chinese population.
    Breast Cancer Res. 2021;23:62.
    PubMed         Abstract available

  37. CATTIN S, Fellay B, Calderoni A, Christinat A, et al
    Circulating immune cell populations related to primary breast cancer, surgical removal, and radiotherapy revealed by flow cytometry analysis.
    Breast Cancer Res. 2021;23:64.
    PubMed         Abstract available

    Breast Cancer Res Treat

  38. LOPRESTI ML, Bian JJ, Sakr BJ, Strenger RS, et al
    Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
    Breast Cancer Res Treat. 2021 Jun 4. pii: 10.1007/s10549-021-06266.
    PubMed         Abstract available

  39. APPELMAN L, Appelman PTM, Siebers CCN, Bult P, et al
    The value of mammography in women with focal breast complaints in addition to initial targeted ultrasound.
    Breast Cancer Res Treat. 2021;185:381-389.
    PubMed         Abstract available

  40. GALMOR L, Bernstein-Molho R, Sklair-Levy M, Madoursky-Feldman D, et al
    Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2021;185:391-399.
    PubMed         Abstract available

  41. CAINI S, Fiorito G, Palli D, Bendinelli B, et al
    Pre-diagnostic DNA methylation patterns differ according to mammographic breast density amongst women who subsequently develop breast cancer: a case-only study in the EPIC-Florence cohort.
    Breast Cancer Res Treat. 2021 Jun 8. pii: 10.1007/s10549-021-06273.
    PubMed         Abstract available

  42. BROWN JC, Sarwer DB, Troxel AB, Sturgeon K, et al
    A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity.
    Breast Cancer Res Treat. 2021 Jun 5. pii: 10.1007/s10549-021-06284.
    PubMed         Abstract available

  43. MORIKAWA A, Grkovski M, Patil S, Jhaveri KL, et al
    A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.
    Breast Cancer Res Treat. 2021 Jun 10. pii: 10.1007/s10549-021-06209.
    PubMed         Abstract available

  44. DAMIN AP
    Reply to the letter on sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer.
    Breast Cancer Res Treat. 2021 Jun 8. pii: 10.1007/s10549-021-06285.

  45. NTELIOPOULOS G, Page K, Hills A, Howarth K, et al
    Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients.
    Breast Cancer Res Treat. 2021 Jun 7. pii: 10.1007/s10549-021-06220.
    PubMed         Abstract available

  46. SZUHANY KL, Malgaroli M, Riley G, Miron CD, et al
    Barriers and engagement in breast cancer survivorship wellness activities.
    Breast Cancer Res Treat. 2021 Jun 7. pii: 10.1007/s10549-021-06279.
    PubMed         Abstract available

  47. POLAT DS, Schopp JG, Arjmandi F, Porembka J, et al
    Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions.
    Breast Cancer Res Treat. 2021;185:479-494.
    PubMed         Abstract available

  48. SADEGHALVAD M, Mohammadi-Motlagh HR, Rezaei N
    Immune microenvironment in different molecular subtypes of ductal breast carcinoma.
    Breast Cancer Res Treat. 2021;185:261-279.
    PubMed         Abstract available

  49. DIFLORIO-ALEXANDER RM, Song Q, Dwan D, Austin-Strohbehn JA, et al
    Fat-enlarged axillary lymph nodes are associated with node-positive breast cancer in obese patients.
    Breast Cancer Res Treat. 2021 Jun 3. pii: 10.1007/s10549-021-06262.
    PubMed         Abstract available

  50. HAGIWARA Y, Sawaki M, Uemura Y, Kawahara T, et al
    Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial.
    Breast Cancer Res Treat. 2021 Jun 2. pii: 10.1007/s10549-021-06253.
    PubMed         Abstract available

  51. SAINI G, Gogineni K, Kittles RA, Aneja R, et al
    Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials.
    Breast Cancer Res Treat. 2021 Jun 2. pii: 10.1007/s10549-021-06264.
    PubMed         Abstract available

  52. SHAH AN, Carroll KJ, Gerratana L, Lin C, et al
    Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer.
    Breast Cancer Res Treat. 2021;187:397-405.
    PubMed         Abstract available

  53. BERNHARDT SM, Dasari P, Glynn DJ, Townsend AR, et al
    Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells.
    Breast Cancer Res Treat. 2021 May 31. pii: 10.1007/s10549-021-06254.
    PubMed         Abstract available

  54. DIBBLE KE, Baumgartner RN, Boone SD, Baumgartner KB, et al
    Physical activity, ethnicity, and quality of life among breast cancer survivors and population-based controls: the long-term quality of life follow-up study.
    Breast Cancer Res Treat. 2021 May 29. pii: 10.1007/s10549-021-06261.
    PubMed         Abstract available

  55. VILLARREAL-GARZA C, Mesa-Chavez F, Garza-Ledezma MRA, Pena-Curiel O, et al
    Impact of chemotherapy regimen and sequence on the effectiveness of scalp cooling for alopecia prevention.
    Breast Cancer Res Treat. 2021;185:453-458.
    PubMed         Abstract available

  56. COX K, Dineen N, Taylor-Phillips S, Sharma N, et al
    Enhanced axillary assessment using intradermally injected microbubbles and contrast-enhanced ultrasound (CEUS) before neoadjuvant systemic therapy (NACT) identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relev
    Breast Cancer Res Treat. 2021;185:413-422.
    PubMed         Abstract available

  57. ORTEGA EXPOSITO C, Falo C, Pernas S, Perez Carton S, et al
    The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials.
    Breast Cancer Res Treat. 2021 Jun 4. pii: 10.1007/s10549-021-06274.
    PubMed         Abstract available


  58. MCCARTHY AM, Ehsan S, Appel S, Welch M, et al
    Risk factors for an advanced breast cancer diagnosis within 2 years of a negative mammogram.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33661.
    PubMed         Abstract available

  59. WHITE DP, Kurian AW, Stevens JL, Liu B, et al
    Receipt of guideline-concordant care among young adult women with breast cancer.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33652.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  60. HELSBY N, Yong M, Burns K, Findlay M, et al
    Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
    Cancer Chemother Pharmacol. 2021 Jun 10. pii: 10.1007/s00280-021-04307.
    PubMed         Abstract available

  61. WANG B, Deng R, Hennig S, Badovinac Crnjevic T, et al
    Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
    Cancer Chemother Pharmacol. 2021 Jun 9. pii: 10.1007/s00280-021-04296.
    PubMed         Abstract available

    Cancer Epidemiol Biomarkers Prev

  62. STURGEON SR, Sela DA, Browne EP, Einson J, et al
    Prediagnostic white blood cell DNA methylation and risk of breast cancer in the Prostate Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort.
    Cancer Epidemiol Biomarkers Prev. 2021 Jun 9. pii: 1055-9965.EPI-20-1717.
    PubMed         Abstract available

  63. ZHANG D, Abraham L, Demb J, Miglioretti DL, et al
    Function-related indicators and outcomes of screening mammography in older women: evidence from the Breast Cancer Surveillance Consortium cohort.
    Cancer Epidemiol Biomarkers Prev. 2021 Jun 2. pii: 1055-9965.EPI-21-0152.
    PubMed         Abstract available

    Cancer Lett

  64. DIMITRAKOPOULOS FI, Kottorou A, Tzezou A
    Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer.
    Cancer Lett. 2021 May 30. pii: S0304-3835(21)00254.
    PubMed         Abstract available

  65. REGUA AT, Arrigo A, Doheny D, Wong GL, et al
    Transgenic mouse models of breast cancer.
    Cancer Lett. 2021;516:73-83.
    PubMed         Abstract available

  66. WANG H, Shi Y, Chen CH, Wen Y, et al
    KLF5-induced lncRNA IGFL2-AS1 promotes basal-like breast cancer cell growth and survival by upregulating the expression of IGFL1.
    Cancer Lett. 2021;515:49-62.
    PubMed         Abstract available

    Cancer Res

  67. YUZEFOVYCH LV, Kahn AG, Schuler MA, Eide L, et al
    Correction: Mitochondrial DNA Repair through OGG1 Activity Attenuates Breast Cancer Progression and Metastasis.
    Cancer Res. 2021;81:3144.

  68. ZHANG H, Zhang N, Liu Y, Su P, et al
    Correction: Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
    Cancer Res. 2021;81:3145.

  69. WANG T, Farvid MS, Kang JH, Holmes MD, et al
    Diabetes Risk Reduction Diet and Survival After Breast Cancer Diagnosis.
    Cancer Res. 2021 Jun 9. pii: 0008-5472.CAN-21-0256.
    PubMed         Abstract available

    Clin Breast Cancer

  70. ZHOU J, Liu Y, Xu M, Mei L, et al
    Management of Breast Cancer Patients During the Coronavirus Disease 2019 Pandemic: The Experience From the Epicenter of China, Wuhan.
    Clin Breast Cancer. 2021 May 6. pii: S1526-8209(21)00114.
    PubMed         Abstract available

  71. SHEIKHHOSSEIN F, Shab-Bidar S, Amini MR, Hosseini F, et al
    Dietary Insulin Index and Insulin Load in Relation to Breast Cancer: Findings from a Case-Control Study.
    Clin Breast Cancer. 2021 Apr 24. pii: S1526-8209(21)00086.
    PubMed         Abstract available

  72. JIA L, Ling Y, Li K, Zhang L, et al
    A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer.
    Clin Breast Cancer. 2021 Apr 29. pii: S1526-8209(21)00088.
    PubMed         Abstract available

    Clin Cancer Res

  73. POTTER DA, Thomas A, Rugo HS
    A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-1133.
    PubMed         Abstract available

  74. ANWAR M, Chen Q, Ouyang D, Wang S, et al
    Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0474.
    PubMed         Abstract available

  75. THOMPSON PA, Huang C, Yang J, Wertheim BC, et al
    Sulindac, a non-selective NSAID, reduces breast density in postmenopausal women with breast cancer treated with aromatase inhibitors.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0732.
    PubMed         Abstract available

  76. CARTER JM, Polley MC, Leon-Ferre RA, Sinnwell J, et al
    Characteristics and spatially-defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0343.
    PubMed         Abstract available

  77. BAI Y, Cole K, Martinez-Morilla S, Ahmed FS, et al
    An Open Source, Automated Tumor Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0325.
    PubMed         Abstract available

  78. WU AML, Gossa S, Samala R, Chung MA, et al
    Aging and CNS myeloid cell depletion attenuate breast cancer brain metastasis.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1549.
    PubMed         Abstract available

  79. BOUGHEY JC, Suman VJ, Yu J, Santo K, et al
    Patient Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY).
    Clin Cancer Res. 2021 Jun 2. pii: 1078-0432.CCR-21-0641.
    PubMed         Abstract available

    Curr Treat Options Oncol

  80. KUMAR NB
    The Promise of Nutrient-Derived Bioactive Compounds and Dietary Components to Ameliorate Symptoms of Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors.
    Curr Treat Options Oncol. 2021;22:67.
    PubMed         Abstract available

    Eur J Cancer

  81. FURLANETTO J, Marme F, Seiler S, Thode C, et al
    Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
    Eur J Cancer. 2021;152:193-203.
    PubMed         Abstract available

  82. BOTTERI E, Baker JG, Sloan EK
    Response to the letter Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
    Eur J Cancer. 2021 Jun 4. pii: S0959-8049(21)00268.

  83. LYNCH SM, Russell NM, Barron S, Wang CA, et al
    Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
    Eur J Cancer. 2021;152:78-89.
    PubMed         Abstract available

  84. GELMON KA, Fasching PA, Couch FJ, Balmana J, et al
    Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Eur J Cancer. 2021;152:68-77.
    PubMed         Abstract available

  85. WOJTYLA C, Bertuccio P, Wojtyla A, La Vecchia C, et al
    European trends in breast cancer mortality, 1980-2017 and predictions to 2025.
    Eur J Cancer. 2021;152:4-17.
    PubMed         Abstract available

  86. DE SANCTIS R, Vigano A, Torrisi R, Santoro A, et al
    Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients: Sympathetic nervous system activity on breast cancer: the story of migraine.
    Eur J Cancer. 2021 May 27. pii: S0959-8049(21)00266.

    Eur Radiol

  87. CANELO-AYBAR C, Taype-Rondan A, Zafra-Tanaka JH, Rigau D, et al
    Preoperative breast magnetic resonance imaging in patients with ductal carcinoma in situ: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC).
    Eur Radiol. 2021 May 30. pii: 10.1007/s00330-021-07873.
    PubMed         Abstract available


  88. KUMAR A, Dhillon A, Manjegowda MC, Singh N, et al
    Estrogen suppresses HOXB2 expression via ERalpha in breast cancer cells.
    Gene. 2021 May 29:145746. doi: 10.1016/j.gene.2021.145746.
    PubMed         Abstract available

    Int J Cancer

  89. AKCAY IM, Celik E, Agaoglu NB, Alkurt G, et al
    Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
    Int J Cancer. 2020 Jul 13. doi: 10.1002/ijc.33199.
    PubMed         Abstract available

  90. LAMEIJER JRC, Nederend J, Voogd AC, Tjan-Heijnen VCG, et al
    Frequency and diagnostic outcome of bilateral recall at screening mammography.
    Int J Cancer. 2021;148:48-56.
    PubMed         Abstract available

  91. PREOBRAZHENSKAYA EV, Shleykina AU, Gorustovich OA, Martianov AS, et al
    Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    Int J Cancer. 2021;148:203-210.
    PubMed         Abstract available

  92. ISHEDEN G, Grassmann F, Czene K, Humphreys K, et al
    Lymph node metastases in breast cancer: investigating associations with tumor characteristics, molecular subtypes, and polygenic risk score using a continuous growth model.
    Int J Cancer. 2021 Jun 7. doi: 10.1002/ijc.33704.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  93. POPPE MM, Khan AJ
    In Reply to Dyer et al.
    Int J Radiat Oncol Biol Phys. 2021;109:301-302.

  94. DYER BA, Flanagan MR, Said HK, Kim J, et al
    In Regard to Poppe et al.
    Int J Radiat Oncol Biol Phys. 2021;109:300-301.

    J Clin Oncol

  95. MAYER IA, Zhao F, Arteaga CL, Symmans WF, et al
    Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
    J Clin Oncol. 2021 Jun 6:JCO2100976. doi: 10.1200/JCO.21.00976.
    PubMed         Abstract available

  96. ROBSON M
    Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2.
    J Clin Oncol. 2021 Jun 9:JCO2100999. doi: 10.1200/JCO.21.00999.
    PubMed         Abstract available

  97. GAO C, Polley EC, Hart SN, Huang H, et al
    Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
    J Clin Oncol. 2021 Jun 8:JCO2001992. doi: 10.1200/JCO.20.01992.
    PubMed         Abstract available

  98. TOLANEY SM, Tayob N, Dang C, Yardley DA, et al
    Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
    J Clin Oncol. 2021 Jun 2:JCO2003398. doi: 10.1200/JCO.20.03398.
    PubMed         Abstract available

    J Natl Cancer Inst

  99. RUGO HS, Loi S, Adams S, Schmid P, et al
    PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2021 Jun 7. pii: 6294407. doi: 10.1093.
    PubMed         Abstract available

  100. DACKUS GM, Jozwiak K, Sonke GS, van der Wall E, et al
    Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients.
    J Natl Cancer Inst. 2021 Jun 8. pii: 6292098. doi: 10.1093.
    PubMed         Abstract available

  101. WAGNER LI, Tooze JA, Hall DL, Levine BJ, et al
    Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results from the FoRtitude Randomized Trial.
    J Natl Cancer Inst. 2021 May 31. pii: 6290009. doi: 10.1093.
    PubMed         Abstract available

  102. VINAYAK S, Davidson NE
    Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought?
    J Natl Cancer Inst. 2021 Jun 8. pii: 6292091. doi: 10.1093.

  103. BLAES A, Konety S, Zordoky B
    Response to Schoormans.
    J Natl Cancer Inst. 2021;113:214-215.

    J Nucl Med

  104. JACENE HA, Liu M, Cheng SC, Abbott A, et al
    Imaging Androgen Receptors in Breast Cancer with (18)F-fluoro-5alpha-dihydrotestosterone-PET: A Pilot Study.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262068. doi: 10.2967/jnumed.121.262068.
    PubMed         Abstract available

    J Pathol

  105. NIU Z, Chen G, Chang W, Sun P, et al
    Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity.
    J Pathol. 2021;253:247-257.
    PubMed         Abstract available


  106. ADLER AI, Latimer NR
    Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical Trials.
    JAMA. 2021;325:2110-2111.

    Lancet Oncol

  107. GANGULY S, Gogia A
    Pembrolizumab monotherapy in advanced triple-negative breast cancer.
    Lancet Oncol. 2021;22:e224.

  108. AMANT F, Lefrere H, Borges VF, Cardonick E, et al
    The definition of pregnancy-associated breast cancer is outdated and should no longer be used.
    Lancet Oncol. 2021;22:753-754.

    N Engl J Med

  109. TUTT ANJ, Garber JE, Kaufman B, Viale G, et al
    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
    N Engl J Med. 2021 Jun 3. doi: 10.1056/NEJMoa2105215.
    PubMed         Abstract available


  110. CORREIA AL, Guimaraes JC, Auf der Maur P, De Silva D, et al
    Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy.
    Nature. 2021 Jun 2. pii: 10.1038/s41586-021-03614.
    PubMed         Abstract available

    NPJ Breast Cancer

  111. GOODWIN PJ, Dowling RJO, Ennis M, Chen BE, et al
    Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial.
    NPJ Breast Cancer. 2021;7:74.
    PubMed         Abstract available

  112. LUO R, Chong W, Wei Q, Zhang Z, et al
    Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer.
    NPJ Breast Cancer. 2021;7:72.
    PubMed         Abstract available

  113. JORGENSEN MG, Toyserkani NM, Hansen FG, Bygum A, et al
    The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment.
    NPJ Breast Cancer. 2021;7:70.
    PubMed         Abstract available

  114. WENNSTIG AK, Wadsten C, Garmo H, Johansson M, et al
    Risk of primary lung cancer after adjuvant radiotherapy in breast cancer-a large population-based study.
    NPJ Breast Cancer. 2021;7:71.
    PubMed         Abstract available

  115. WARNER ET, Rice MS, Zeleznik OA, Fowler EE, et al
    Automated percent mammographic density, mammographic texture variation, and risk of breast cancer: a nested case-control study.
    NPJ Breast Cancer. 2021;7:68.
    PubMed         Abstract available

  116. TU Z, Schmoellerl J, Mariani O, Zheng Y, et al
    The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer.
    NPJ Breast Cancer. 2021;7:69.
    PubMed         Abstract available

  117. ZAHAVI T, Salmon-Divon M, Salgado R, Elkin M, et al
    Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.
    NPJ Breast Cancer. 2021;7:67.
    PubMed         Abstract available

  118. BUSHNELL GG, Deshmukh AP, den Hollander P, Luo M, et al
    Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge.
    NPJ Breast Cancer. 2021;7:66.
    PubMed         Abstract available


  119. QIAO Y, Jin T, Guan S, Cheng S, et al
    Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01845.
    PubMed         Abstract available

  120. TRUONG TH, Benner EA, Hagen KM, Temiz NA, et al
    PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER(+) breast cancer.
    Oncogene. 2021 Jun 8. pii: 10.1038/s41388-021-01871.
    PubMed         Abstract available

  121. SHARIATI M, Evans KW, Zheng X, Bristow CA, et al
    Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
    Oncogene. 2021 Jun 9. pii: 10.1038/s41388-021-01819.
    PubMed         Abstract available

    Oncol Rep

  122. FERRETTI VA, Canzoneri R, Palma S, Lacunza E, et al
    RHBDD2WWOX protein interaction during proliferative and differentiated stages in normal and breast cancer cells.
    Oncol Rep. 2021;46.
    PubMed         Abstract available


  123. PAIK HJ, Jung YJ, Kim DI, Lee S, et al
    Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.
    Oncology. 2021 Jun 7:1-8. doi: 10.1159/000515790.
    PubMed         Abstract available

    PLoS One

  124. ZHU L, Cui K, Weng L, Yu P, et al
    A panel of 8-lncRNA predicts prognosis of breast cancer patients and migration of breast cancer cells.
    PLoS One. 2021;16:e0249174.
    PubMed         Abstract available

  125. DING H, Buzzard GW, Huang S, Sehorn MG, et al
    MICA-G129R: A bifunctional fusion protein increases PRLR-positive breast cancer cell death in co-culture with natural killer cells.
    PLoS One. 2021;16:e0252662.
    PubMed         Abstract available

  126. AL-KEILANI MS, Elstaty RI, Alqudah MA, Alkhateeb AM, et al
    Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index.
    PLoS One. 2021;16:e0252616.
    PubMed         Abstract available

  127. WATANABE T, Oba T, Tanimoto K, Shibata T, et al
    Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
    PLoS One. 2021;16:e0252822.
    PubMed         Abstract available

  128. KANG Z, Chen S, Shi L, He Y, et al
    Predictors of heart and lung dose in left-sided breast cancer treated with VMAT relative to 3D-CRT: A retrospective study.
    PLoS One. 2021;16:e0252552.
    PubMed         Abstract available

  129. PODUVAL D, Sichmanova Z, Straume AH, Lonning PE, et al
    Correction: The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer.
    PLoS One. 2021;16:e0253361.
    PubMed         Abstract available

  130. AKLILU S, Bain C, Bansil P, de Sanjose S, et al
    Evaluation of diagnostic ultrasound use in a breast cancer detection strategy in Northern Peru.
    PLoS One. 2021;16:e0252902.
    PubMed         Abstract available

  131. LEE J, Kang BJ, Kim SH
    Usefulness of postoperative surveillance MR for women after breast-conservation therapy: Focusing on MR features of early and late recurrent breast cancer.
    PLoS One. 2021;16:e0252476.
    PubMed         Abstract available

  132. YOSHIKAWA K, Ishida M, Yanai H, Tsuta K, et al
    Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
    PLoS One. 2021;16:e0253176.
    PubMed         Abstract available

  133. Retraction: AIB1 Cooperates with ERalpha to Promote Epithelial Mesenchymal Transition in Breast Cancer through SNAI1 Activation.
    PLoS One. 2021;16:e0252791.


    MRI Screening of Women with a Personal History of Breast Cancer.
    Radiology. 2021 Jun 8:211080. doi: 10.1148/radiol.2021211080.

  135. KIM GR, Cho N, Kim SY, Han W, et al
    Interval Cancers after Negative Supplemental Screening Breast MRI Results in Women with a Personal History of Breast Cancer.
    Radiology. 2021 Jun 8:203074. doi: 10.1148/radiol.2021203074.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.